Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease

Levels of soluble receptor for advanced glycation endproducts (sRAGE) have been linked to several components of the metabolic syndrome. We tested the hypothesis that plasma levels of sRAGE may be associated with non-alcoholic fatty liver disease. We enrolled subjects with definite nonalcoholic steat...

Full description

Saved in:
Bibliographic Details
Published in:Clinical biochemistry 2009-06, Vol.42 (9), p.802-807
Main Authors: Yilmaz, Yusuf, Ulukaya, Engin, Gul, Ozen Oz, Arabul, Mahmut, Gul, Cuma Bulent, Atug, Ozlen, Oral, Arzu Yilmaztepe, Aker, Sibel, Dolar, Enver
Format: Article
Language:English
Subjects:
Adult
Biological markers
Enzyme-Linked Immunosorbent Assay
Fatty liver
Fatty Liver - blood
Humans
Middle Aged
Receptor for Advanced Glycation End Products
Receptor for advanced glycation endproducts (RAGE)
Receptors, Immunologic - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Levels of soluble receptor for advanced glycation endproducts (sRAGE) have been linked to several components of the metabolic syndrome. We tested the hypothesis that plasma levels of sRAGE may be associated with non-alcoholic fatty liver disease. We enrolled subjects with definite nonalcoholic steatohepatitis (NASH, n = 40), borderline NASH ( n = 8), simple fatty liver ( n = 9) and healthy controls ( n = 14). Plasma levels of sRAGE were measured by ELISA. Concentrations of sRAGE were significantly lower in patients with definite NASH (1080 ± 392 pg/mL, P < 0.01) and borderline NASH (1050 ± 278 pg/mL, P < 0.05) compared to controls (1480 ± 387 pg/mL). Levels of sRAGE were significantly and inversely correlated with ALT ( r = − 0.30, P < 0.05) and AST ( r = − 0.23, P < 0.05). Plasma levels of sRAGE are significantly reduced in definite and borderline NASH.
ISSN:0009-9120
1873-2933
DOI:10.1016/j.clinbiochem.2009.02.003